Discovery of a novel 10-hydroxy-12-methyl-substituted evodiamine derivative with anti-hepatocellular carcinoma activity through multi-pathway modulation involving suppression of PKA/AKT signaling cascades and moderate Topo I inhibition.
Aug 2026· European journal of medicinal chemistry· Vol 319, pp.
119226
· 0 citations· 38 references
Medicine
TL;DR
Z4 more effectively inhibited proliferation and migration/invasion of BEL-7404 and HuH-7 cells than sorafenib, while inducing cell cycle arrest, mitochondrial dysfunction, reactive oxygen species (ROS) accumulation, and apoptosis, and provides a promising lead compound Z4 for anti-HCC drug discovery.
Abstract
Hepatocellular carcinoma (HCC) is a highly lethal malignancy with poor prognosis. The clinical benefits of small-molecule therapeutics represented by sorafenib remain limited, underscoring the urgent need to continuously invest in the discovery of novel anti-HCC lead compounds. In this study, structural optimization of the previously identified compound 6f with anti-HCC potential was conducted through diverse substituent modifications on the A- and E-rings, accompanied by systematic structure-activity relationship (SAR) investigations. This effort led to the identification of a new lead compound, Z4, which exhibited potent nanomolar inhibitory activity against four HCC cell lines (IC50 = 0.08 μM for HepG2, 0.16 μM for SK-Hep-1, 0.03 μM for HuH-7, and 0.03 μM for BEL-7404) as well as a doxorubicin-resistant cell line (IC50 = 0.19 μM for SMMC-7721/DOX). Cell-based phenotypic evaluations further demonstrated that Z4 more effectively inhibited proliferation and migration/invasion of BEL-7404 and HuH-7 cells than sorafenib, while inducing cell cycle arrest, mitochondrial dysfunction, reactive oxygen species (ROS) accumulation, and apoptosis. Mechanistically, Z4 exerts its anti-HCC activity primarily through synergistic inhibition of the cAMP-PKA-CREB and PI3K-AKT-mTOR pathways, with only moderate Topo I inhibition observed at high concentrations. In addition, in vivo studies indicated that Z4 possesses acceptable metabolic stability (T1/2 = 8.96 h) and exhibits significantly superior antitumor efficacy compared to sorafenib in a HuH-7 xenograft model. Collectively, this study not only further enriches the SAR of the A-ring of the evodiamine scaffold but also provides a promising lead compound Z4 for anti-HCC drug discovery.
The combined results underscore the promise of the cyanopyridine scaffold as a framework for developing selective multi-target anticancer medicines and identify compound 2b as the most selective and potent derivative in the series.
Shimaa M. Alhamaky, Marwa S. A. Hassan, Eman M. Ahmed et al.· Bioorganic chemistry (Print)· 0 citations
TMLB-G9 is a promising B3GAT3 inhibitor worthy of further development for HCC therapy and exhibits superior anti-HCC activity to TMLB-C16 in two HCC xenograft models.
Hao Yin, Xiao-Wen Yan, Bo Fan et al.· Journal of Medicinal Chemist...· 0 citations
A new series of quinoline-diphenylpyrazole hybrids were rationally designed, synthesized, and biologically evaluated as potential EGFR/VEGFR-2/COX-2 inhibitors, supporting the proposed hybrid design strategy.
Abdelrahman Hamdi, Mohamed R. Elnagar, M. Hussein et al.· Bioorganic chemistry (Print)· 0 citations
In vivo validation in PC-3 xenograft mice confirmed that 11 M exerted robust tumor growth suppression with low systemic toxicity, accompanied by DNMT3A downregulation and MAPK pathway activation, substantiating its multi-target therapeutic mechanism.
PKMYT1 is a critical regulator of the cell cycle and has emerged as a promising synthetic lethal target for CCNE1-amplified cancers. In this study, we report the design, synthesis, and biological evaluation of a novel series of 4-aminoquinazoline-based PKMYT1 inhibitors. A hydrogen bond donor-to-acceptor conversion str...
Hai-Xiang Qi, Rui Lu, Yi-Fei Zhu et al.· Journal of Medicinal Chemist...· 0 citations